A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea

Trial Profile

A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Erythema
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Feb 2014 New trial record
    • 29 Jan 2014 Study results were published in the Journal of Drugs in Dermatology, according to a Galderma Laboratories media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top